Advances in targeting the WNT/β-catenin signaling pathway in cancer
Drug Discovery Today, ISSN: 1359-6446, Vol: 27, Issue: 1, Page: 82-101
2022
- 72Citations
- 98Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations72
- Citation Indexes72
- 72
- CrossRef20
- Captures98
- Readers98
- 98
Review Description
WNT/β-catenin signaling orchestrates various physiological processes, including embryonic development, growth, tissue homeostasis, and regeneration. Abnormal WNT/β-catenin signaling is associated with various cancers and its inhibition has shown effective antitumor responses. In this review, we discuss the pathway, potential targets for the development of WNT/β-catenin inhibitors, available inhibitors, and their specific molecular interactions with the target proteins. We also discuss inhibitors that are in clinical trials and describe potential new avenues for therapeutically targeting the WNT/β-catenin pathway. Furthermore, we introduce emerging strategies, including artificial intelligence (AI)-assisted tools and technology-based actionable approaches, to translate WNT/β-catenin inhibitors to the clinic for cancer therapy.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1359644621003172; http://dx.doi.org/10.1016/j.drudis.2021.07.007; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85111518850&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/34252612; https://linkinghub.elsevier.com/retrieve/pii/S1359644621003172; https://dx.doi.org/10.1016/j.drudis.2021.07.007
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know